This innovative strategy addresses several critical limitations of current therapies by offering (1): catalytic, long-lasting effects that enable less frequent dosing (2); elimination of both enzymatic and scaffolding functions of STING; and (3) broad potential applicability across autoimmune disorders, fibrotic conditions, and neurodegenerative diseases. Here, STING1 is linked to autoimmune disease.